Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives

Overview

Journal Cell Mol Immunol

Date 2024 Oct 15

PMID 39406966

Authors

Yang Liu

Fei Zhou

Heba Ali

Justin D Lathia

Peiwen Chen

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers. However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential molecular mechanisms underlying immunotherapy resistance in GBM. Furthermore, we provide an in-depth discussion regarding the strategies that can overcome immunotherapy resistance in GBM, which will likely require combination therapies.

Citing Articles

Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.

Yuzhakova D, Sachkova D, Shirmanova M, Shcheslavskiy V, Mozherov A, Dashinimaev E Sovrem Tekhnologii Med. 2025; 17(1):109-118.

PMID: 40071076 PMC: 11892565. DOI: 10.17691/stm2025.17.1.10.

IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment.

Lee G, Hsu J, Chang Y, Hsieh L, Li Y, Wu Y J Biomed Sci. 2025; 32(1):34.

PMID: 40057744 PMC: 11889942. DOI: 10.1186/s12929-025-01126-w.

Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy.

Eckert T, Zobaer M, Boulos J, Alexander-Bryant A, Baker T, Rivers C Cancers (Basel). 2025; 17(3).

PMID: 39941829 PMC: 11816167. DOI: 10.3390/cancers17030462.

Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy.

Cai Y, Xiao H, Xue S, Li P, Zhan Z, Lin J J Exp Clin Cancer Res. 2025; 44(1):35.

PMID: 39901195 PMC: 11789371. DOI: 10.1186/s13046-025-03301-1.

Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma.

Liu J, Dai K, Saliu M, Salisu M, Gan J, Afolabi L Front Immunol. 2025; 15:1519777.

PMID: 39877353 PMC: 11772361. DOI: 10.3389/fimmu.2024.1519777.

References

Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D . Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7(10):859-66. DOI: 10.1038/sj.gt.3301184. View

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

Lun M, Lok E, Gautam S, Wu E, Wong E . The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. 2011; 105(2):261-73. DOI: 10.1007/s11060-011-0575-8. View

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M . A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 2018; 21(3):348-359. PMC: 6380422. DOI: 10.1093/neuonc/noy200. View

Smyth M, Dunn G, Schreiber R . Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90:1-50. DOI: 10.1016/S0065-2776(06)90001-7. View

Shaw R, Basu M, Karmakar S, Ghosh M . MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives. Biochim Biophys Acta Mol Cell Res. 2024; 1871(3):119673. DOI: 10.1016/j.bbamcr.2024.119673. View

Lee A, Sun L, Mochizuki A, Reynoso J, Orpilla J, Chow F . Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021; 12(1):6938. PMC: 8626557. DOI: 10.1038/s41467-021-26940-2. View

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

Hong M, Clubb J, Chen Y . Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020; 38(4):473-488. DOI: 10.1016/j.ccell.2020.07.005. View

10.

Kim M, Ladomersky E, Mozny A, Kocherginsky M, OShea K, Reinstein Z . Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021; 3(1):vdab125. PMC: 8500689. DOI: 10.1093/noajnl/vdab125. View

11.

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J . Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28(8):1630-1639. PMC: 9388376. DOI: 10.1038/s41591-022-01897-x. View

12.

Shibuya M . Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2012; 153(1):13-9. PMC: 3528006. DOI: 10.1093/jb/mvs136. View

13.

Medawar P . Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948; 29(1):58-69. PMC: 2073079. View

14.

Chiocca E, Rabkin S . Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014; 2(4):295-300. PMC: 4303349. DOI: 10.1158/2326-6066.CIR-14-0015. View

15.

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

16.

Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R . Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2017; 78(1):256-264. PMC: 5754236. DOI: 10.1158/0008-5472.CAN-17-0469. View

17.

Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10):867-74. DOI: 10.1038/sj.gt.3301205. View

18.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y . Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023; 8(1):149. PMC: 10081433. DOI: 10.1038/s41392-023-01408-5. View

19.

Barnett A, Ozair A, Bamashmos A, Li H, Bosler D, Yeaney G . MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma. Cancers (Basel). 2024; 16(7). PMC: 11011031. DOI: 10.3390/cancers16071374. View

20.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View